Chinese patent granted 

• Major commercial milestone reached with the grant of a patent protecting the 12CQ quantum computing chip in the world’s second largest economy.

• Chinese patent for the 12CQ chip is a significant validation of the technology’s industrial and technical global competitive advantage.

• China has over 2.6 million patents in force, second only to the US, with foreign patent applications mostly from the US, making China one of the biggest innovation economies in the world.

• Archer is the only ASX listed company and one of a few players in the world developing a qubit processor chip in the quantum computing industry†.

• Archer achieves a key technological milestone in the development of its 12CQ quantum computing qubit processor chip technology.

• The work represents a significant technical achievement because the electronic transport measurements were performed on a single qubit – only a few hundred atoms across – and at room temperature.

• The Company utilised over $150 million of semiconductor foundry facilities and some of the most advanced instrumentation in the world to complete its most recent validation of the 12CQ technology.

• Archer is one of only a few players† developing a qubit processor chip in the emerging multibillion-dollar quantum computing industry‡.

First patent granted for 12CQ quantum computing chip Highlights

• Japanese patent granted for Archer’s 12CQ quantum computing qubit processor (“chip”).

• Major commercial milestone achieved with the grant of a patent protecting the 12CQ chip technology in a Top 5 global economy.

• Archer is one of few key players† developing a qubit processor chip in the emerging multibillion-dollar quantum computing industry‡. 

The JP Patent (Patent No. 6809670) is the first granted patent protecting the 12CQ chip. The grant of the JP Patent represents a significant commercial milestone in Archer’s development of the 12CQ chip.

The grant of the JP Patent gives Archer access to the high-value Japanese market for the 12CQ chip and is the first step in the Company’s efforts to access global markets. The JP Patent application successfully underwent substantive examination procedures in Japan by the Japan Patent Office§ , which is one of the world’s largest patent offices.

The success in the grant of the JP patent streamlines the patent granting process and procedures for the additional six international patent applications in the jurisdictions of Australia, South Korea, Hong Kong, China, Europe, and the US (ASX ann. 6 Oct 2020). The Company considers Japan as a critical strategic jurisdiction to protect and commercialise its IP. Japan is a major global economy** and according to the World Economic Forum, ranks amongst the top 5 economies in the world for global competitiveness and GDP.

Commenting on the grant of the Japanese patent, Archer CEO Dr Mohammad Choucair said: “Archer’s quantum computing chip IP is now well protected in Japan – a major global economy and centre for technological innovation.

The grant of a patent in Japan further validates, and substantially derisks, our unique technology. “Archer is one of very few companies in the world with a patent portfolio protecting quantum computing qubit processor technology, and this is strategically significant as we rapidly progress in commercialising the 12CQ chip.”

Quantum collaboration with leading AI firm Max Kelsen
Highlights
• Archer and Max Kelsen will develop quantum algorithms relevant to the
operation of the 12CQ quantum computing processor (“chip”).
• The Australian companies are members of the IBM Q Network†, and will use
IBM’s Qiskit and quantum computers for testing and validation.
• The collaboration is a key step in the commercialisation of the 12CQ chip,
and aims to validate chip end-uses and high-value practical applications.
• Quantum computing outcomes from the collaboration will target multiple
sectors, including ICT and financial services‡.
Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”) is pleased to announce that it
has entered into a collaboration with a leading Artificial Intelligence and Machine Learning
company, Max Kelsen (“the Collaboration”). Archer and Max Kelsen are members of the global
IBM Q Network†
.
The collaboration is a critical step in the commercialisation of the 12CQ chip because the
principal purpose of building quantum computing processors is to apply and run quantum
algorithms to generate value from outperforming modern computing.
Commenting on the collaboration, Archer CEO Dr Mohammad Choucair said: “As part of
Archer’s forward looking strategy, the partnership with Max Kelsen – a leading AI and Quantum
Computing firm – is a key step forward in the commercialisation of our 12CQ chip technology.
“It’s a great example of how two Australian IBM Q Network Members are working together to
realise the commercial potential of quantum computing.
“We will use IBM’s Qiskit and quantum machines to validate our work, and once validated,
Archer intends to apply the end-user cases, algorithms and Qiskitto 12CQ chip hardware, which
demonstrates the increasing value our partnerships bring as we progress in our development.”
As IBM Q Network members, Archer and Max Kelsen will use IBM’s Qiskit open source
programming framework and cloud-based quantum computers to implement novel quantum
algorithms developed that validate practical quantum computing applications relevant to
Archer’s 12CQ chip technology, i.e. real uses that would benefit from quantum processors
onboard technology at room temperature.
† https://www.nature.com/articles/s42254-020-00247-5; also https://www.ibm.com/quantumcomputing/network/members/
‡ https://www.bcg.com/en-au/publications/2020/how-financial-institutions-can-utilize-quantum-computing
Advanced Materials Archer Materials Limited (ACN: 123 993 233)
12CQ Ground Floor, 28 Greenhill Road, SA 5034
As part of the Collaboration, Archer staff will work directly with the quantum computing team
at Max Kelsen to develop industrially relevant business use-cases of the 12CQ technology for a
number of sectors with the potential for high-value add, including finance‡ and
telecommunications§
. This will involve the use of quantum processors to run quantum
algorithms that have real applications such as Quantum Artificial Neural Networks.
About 12CQ
12CQ is a world-first quantum processor technology that Archer aims to build for quantum
computing operation at room-temperature and integration onboard modern electronic devices.
For more information, please view Archer’s a recent webinar held with IBM.
About Max Kelsen
Founded in Brisbane in 2015, Max Kelsen is a globally leading Artificial Intelligence (AI) and
Machine Learning (ML) software business. Max Kelsen enables innovation directly linked to the
generation of business value and competitive advantage, including for Fortune 500 companies
and some of Australia’s most iconic brands. Max Kelsen’s solutions are at the heart of workflow
automation and value extraction from data, providing extremely accurate predictive modelling
in critical systems like clinical decision making. Max Kelsen is also dedicated to reinvesting its
expertise and profits to solve the challenges of humankind, focusing on Cancer Genomics, AI
Safety, and Quantum Computing. Max Kelsen was the Amazon Web Services (AWS) Partner of
the Year in 2020 for Data and AI

This company keeps on innovating.....announcing 
Archer’s A1 Biochip™ 

• Archer commences its A1 Biochip™ development with the aim of building a lab-on-chip biosensing device capable of simplifying disease detection.

• The A1 Biochip™ is being built by the Archer team in a world-class semiconductor chip prototyping foundry.

• Archer is working with a German biotech company to explore the on-chip conversion of in-demand commercial diagnostics.

• Lab-on-chip devices form part of the global multibillion dollar biotech economy, catalysed by advances in point of care diagnostics and testing1.

• Archer owns all the IP associated to the biochip technology, and the Company is prosecuting related international patent applications.  

Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”) is pleased to announce the Company has commenced building a lab-on-a-chip device (“biochip”) named A1 Biochip™.

Archer has made a step-change in advancing its graphene-based biosensor technology development to newly commence its lab-on-a-chip A1 Biochip™ project. This was possible in a short period of time as Archer brought its biotechnology development in-house and is now able
to miniaturise its biosensing processes to chip-formats while retaining its IP.

Archer will be designing and building its own biochip which means that the Company no longer requires prototyping sensor materials, graphene inks, 2D/3D printing, or circuit boards (manufactured in Asia) (ASX Ann. 31 Aug 2020). Developing the biochip in-house should allow Archer to accelerate commercialisation of the biochip.

Commenting on the A1 Biochip™ development, Archer CEO Dr Mohammad Choucair said: “It is a global challenge to develop innovative biodevices that make the complex detection of disease safer and more reliable. Archer’s A1 Biochip™ technology aims to simplify disease detection at the point of care to potentially address an emerging multibillion dollar industry.

“Archer’s biochip development involves miniaturising medical lab tests onto an integrated circuit, a single chip, that is only a few millimetres in size. This is incredibly difficult, and there
are very few people the world that can do this type of work, however Dr Soffe has already made exciting advances on this front in only a few weeks since joining Archer”.

Archer have developed quantum computing technology allowing chip to function in room temperature, opening possibilities for quantum computing to be utilised in mainstream computers. See ASX announcement below for IBM agreement...

• Archer signs an agreement with IBM to advance quantum computing and work towards solutions for the widescale adoption of the technology. • Archer is the first Australian company building a quantum computing qubit processor to join the global IBM Q Network as an ecosystem partner. • IBM staff will work directly with the Archer team who will gain access to IBM's quantum computing expertise and resources to enable a broader hardware ecosystem using IBM’s open source software framework, Qiskit. • Archer is considerably advancing the commercial readiness of its 12CQ qubit processor chip technology towards a minimum viable product. • The intellectual property rights protecting the 12CQ qubit processor chip technology are exclusively held by Archer.